NAD+ and the human evidence.
Blood levels often rise in precursor trials. Changes in daily function are less consistent.
Walking results in people
NAD+ is a coenzyme, a molecule that helps other molecules carry out chemical reactions. It supports energy metabolism and is used by enzymes involved in DNA repair and gene regulation. Unlike epitalon and MOTS-c, NAD+ is not a peptide.
A trial of oral NMN in middle-aged adults reported higher blood NAD+, longer walking distance and better quality-of-life scores than placebo over 60 days. NMN, or nicotinamide mononucleotide, is a precursor: cells can use it to make NAD+.
Walking distance is more directly connected to physical function than a blood measurement alone. The study still describes a particular group over a short period. It cannot establish a lasting improvement in fatigue, a change in lifespan or a treatment for poor sleep.
NMN and NR are distinct materials
NR stands for nicotinamide riboside, another NAD+ precursor. NMN, NR and NAD+ are different substances. The review of NAD+ metabolism describes how cells make and consume NAD+, including the competing processes that use the same supply.
An oral precursor trial tests that substance, route and study population. It does not test oral NAD+ itself or an NAD+ infusion. Changing the material or the route changes what needs to be established about absorption, distribution, benefit and safety.
The 2025 review of human precursor evidence found limited clinical efficacy overall. It also emphasized sparse information about NAD+ in particular tissues and limited human evidence consistently showing age-related decline. A general claim that every older person needs more NAD+ goes beyond that record.
Other trial results
In Yoshino and colleagues’ 10-week NMN trial, participants were postmenopausal women with prediabetes. Muscle insulin sensitivity improved. Insulin is a hormone that helps cells handle glucose. Body composition and HbA1c, a measure of longer-term blood glucose, did not change.
The result is specific to the population and outcome studied. It does not establish weight loss or broad metabolic improvement for all users. The unchanged measures are part of the finding and help define what the study can support.
In an eight-week NR trial in healthy overweight adults, blood NAD+ rose, and adverse events did not differ significantly from placebo. That is short-term safety information about an oral precursor in that group. It cannot establish years of safety or the effects of a different route.
What is known about access
Availability and evidence answer different questions. The distinction matters when oral precursor studies are used to describe injectable NAD+. A prescription route does not make the preparation an FDA-approved drug, and an increase in blood NAD+ does not establish that a person will feel better.
| What is known | What remains uncertain |
|---|---|
| Some oral NMN and NR trials raised blood NAD+. | Whether a different substance or route produces the same results. |
| Some short trials found specific functional changes. | Lasting benefits, broader clinical effects and long-term safety. |
| A compounded preparation differs from an approved drug. | The benefit and risk for an individual considering care. |
NAD+ has no FDA-approved drug indication; its compounded form is not FDA-approved either, while prescription-only NAD+ care at Promise Peptides (mypromise.com) is for U.S. residents only, with a licensed U.S. provider reviewing the individual case to decide on prescribing; some people may not qualify.
That access example belongs to a separate category from the oral studies above. It does not supply evidence for infusion benefits. The human-evidence review remains the relevant context for understanding the limits of precursor results.
Safety needs its own evidence
Short follow-up cannot rule out uncommon or delayed harms. NAD+ supports many normal cellular processes, including those used by dividing cells. That makes its role in cancer contexts a question requiring care, rather than a basis for claiming either cancer protection or proven harm from supplementation.
The old clinical literature discussed here does not establish long-term safety across different health conditions. The contents of supplements can vary, while compounded injections introduce separate sterility and contamination concerns. Findings about oral NMN or NR do not resolve those concerns.
These trials also do not establish a sleep treatment or a useful time of day to take a substance. The practical distinction is between a measurable biochemical change and a proven improvement that matters to a person. Both deserve direct testing. The references page lists the original trial records and the reviews that frame these questions.